May 18, 2022

BONESUPPORT receives market authorization for CERAMENT G in the US

Published: 2022-05-18 BONESUPPORT ™, an emerging leader in orthobiologics for the management of bone injuries, today announced that the company has received market authorizat...
Read more
May 16, 2022

Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing no...
Read more
May 12, 2022

Xeris Announces Full Results From the Logics Study of Recorlev® and Presentation of New Burden of Illness in Cushing’s Syndrome Data at AACE Annual Meeting May 12-14

CHICAGO--(BUSINESS WIRE)--May 12, 2022-- Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for p...
Read more
May 12, 2022

Targovax ASA: First quarter 2022 results

Oslo, Norway, 12 May 2022 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces i...
Read more
May 11, 2022

Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update

25% Enrollment Achieved in CAHmelia-203 Study for Adult Classic CAH; On Track to Report Topline Data in 2H 2023 Debt Facility with Silicon Valley Bank Amended to Provide Up to ...
Read more
May 11, 2022

Aro Biotherapeutics to Present New Preclinical Data Highlighting the Potential of Centyrin-siRNA Conjugates for the Treatment of Pompe Disease

Results of recent studies demonstrate that Aro’s muscle-targeted Centyrin-siRNA conjugate robustly reduces toxic accumulation of muscle glycogen in a murine model of Pompe disea...
Read more
May 11, 2022

Targovax announces clinical collaboration with Agenus for upcoming ONCOS-102 phase 2 melanoma trial

Targovax and Agenus have entered into a clinical collaboration agreement for the ONCOS-102 melanoma phase 2 multi-cohort trial ONCOS-102 will be tested in combination with th...
Read more
May 11, 2022

Xeris Biopharma Reports First Quarter Financial Results and Upcoming Events

Launched Recorlev® and Gvoke® Kit Achieved Q1 net product revenue of $21.9M – a 33% increase from same period prior year on a pro forma basis Ended Q1 with&nbs...
Read more
May 11, 2022

Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

2022-05-11 The following resolutions were passed at the annual general meeting (the “AGM”) of Vicore Pharma Holding AB (publ) on 11 May 2022. Adoption of income statemen...
Read more
May 11, 2022

Targovax to present at upcoming conferences

Oslo, 11 May 2022 – Targovax ASA announces that members of its executive management team and key scientist are invited to present at upcoming conferences: 33rd ...
Read more